Benzinga.com

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer

FDA grants Priority Review to AstraZeneca’s Imfinzi sBLA for muscle-invasive bladder cancer, with decision expected in Q2 2025. Imfinzi regimen showed a 32% reduced risk of disease progression and a ...
Hosted on MSN

AstraZeneca’s IMFINZI® Granted Priority Review for Early-Stage Gastric Cancer Treatment

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in ...

AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug

AstraZeneca PLC (NYSE:AZN) is among the Best Biotech Stocks. On May 1, CNBC reported that an FDA advisory panel voted 6-3 ...

AstraZeneca's Imfinzi combo shows survival benefit in pivotal bladder cancer study

AstraZeneca PLC AZN on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with ...
Reuters

AstraZeneca's Imfinzi gets FDA priority review for type of lung cancer

Aug 15 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Thursday the U.S. Food and Drug Administration (FDA) has granted its blockbuster cancer drug Imfinzi a priority review for patients with ...